Suppr超能文献

肺腺癌中与患者种族相关的基因组特征。

Genomic profiles specific to patient ethnicity in lung adenocarcinoma.

机构信息

Genome Institute of Singapore, Genome, Singapore.

出版信息

Clin Cancer Res. 2011 Jun 1;17(11):3542-50. doi: 10.1158/1078-0432.CCR-10-2185. Epub 2011 Apr 26.

Abstract

PURPOSE

East-Asian (EA) patients with non-small-cell lung cancer (NSCLC) are associated with a high proportion of nonsmoking women, epidermal growth factor receptor (EGFR)-activating somatic mutations, and clinical responses to tyrosine kinase inhibitors. We sought to identify novel molecular differences between NSCLCs from EA and Western European (WE) patients.

EXPERIMENTAL DESIGN

A total of 226 lung adenocarcinoma samples from EA (n = 90) and WE (n = 136) patients were analyzed for copy number aberrations (CNA) by using a common high-resolution SNP (single nucleotide polymorphism) microarray platform. Univariate and multivariate analyses were carried out to identify CNAs specifically related to smoking history, EGFR mutation status, and ethnicity.

RESULTS

The overall genomic profiles of adenocarcinomas from EA and WE patients were highly similar. Univariate analyses revealed several CNAs significantly associated with ethnicity, EGFR mutation, and smoking, but not to gender, and KRAS or p53 mutations. A multivariate model identified four ethnic-specific recurrent CNAs-significantly higher rates of copy number gain were observed on 16p13.13 and 16p13.11 in EA tumors, whereas higher rates of genomic loss on 19p13.3 and 19p13.11 were observed in tumors from WE patients. We identified several potential driver genes in these regions, showing a positive correlation between cis-localized copy number changes and transcriptomic changes.

CONCLUSION

16p copy number gains (EA) and 19p losses (WE) are ethnic-specific chromosomal aberrations in lung adenocarcinoma. Patient ethnicity should be considered when evaluating future NSCLC therapies targeting genes located on these areas.

摘要

目的

东亚(EA)非小细胞肺癌(NSCLC)患者以不吸烟的女性、表皮生长因子受体(EGFR)激活的体细胞突变以及对酪氨酸激酶抑制剂的临床反应比例高为特征。我们试图确定来自 EA 和西欧(WE)患者的 NSCLC 之间的新的分子差异。

实验设计

使用常见的高分辨率 SNP(单核苷酸多态性)微阵列平台,对来自 EA(n=90)和 WE(n=136)患者的 226 例肺腺癌样本进行了拷贝数异常(CNA)分析。进行了单变量和多变量分析,以确定与吸烟史、EGFR 突变状态和种族特异性相关的 CNA。

结果

EA 和 WE 患者的腺癌总体基因组图谱非常相似。单变量分析显示了一些与种族、EGFR 突变和吸烟显著相关的 CNA,但与性别、KRAS 或 p53 突变无关。多变量模型确定了四个与种族特异性相关的复发性 CNA-EA 肿瘤中 16p13.13 和 16p13.11 的拷贝数增益率更高,而 WE 患者的肿瘤中 19p13.3 和 19p13.11 的基因组丢失率更高。我们在这些区域中鉴定了几个潜在的驱动基因,显示了顺式定位的拷贝数变化与转录组变化之间的正相关关系。

结论

16p 拷贝数增加(EA)和 19p 丢失(WE)是肺腺癌中特有的种族特异性染色体异常。在评估针对这些区域的基因的未来 NSCLC 治疗方法时,应考虑患者的种族。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验